Treatment with Convalescent Plasma for Influenza A (H5N1) Infection
To the Editor: A previously healthy 31-year-old male van driver presented to a local clinic in Shenzhen, in southern China, on June 7, 2006, with a 4-day history of a high fever (temperature, 39.9°C), chills, and a cough with clear sputum. A chest radiograph obtained on June 9 revealed large opacities in the lower lobe of the left lung. A reversetranscriptase-polymerase-chain-reaction (RT-PCR) assay and an isolate from a tracheal aspirate were positive for influenza A (H5N1) virus. Treatment with 150 mg of oseltamivir twice daily was started at 2 a.m. on June 12 (Fig. 1) were given to our patient; one was given at 2 a.m. 
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Tissue-Engineered Blood Vessel for Adult Arterial Revascularization
To the Editor: A material that will approach the efficacy of native vein has been widely sought. 1 Using autologous cells and a technique termed sheet-based tissue engineering, we were able to produce autologous tissue-engineered blood vessels with physiologic mechanical properties. 2 No synthetic or exogenous materials were used; instead, the vessels were created with the use of autologous fibroblasts and endothelial cells harvested from a small biopsy specimen of skin and superficial vein. Here we report on the preliminary use of these tissue-engineered blood vessels in an adult arterial model. Ten patients receiving hemodialysis whose arteriovenous shunts were failing were enrolled in this study. The subjects had typical risk factors for end-stage renal disease, including previously failed dialysis-access grafts, diabetes, controlled hyper-
